---
title: 'Diagnosis, treatment, management and monitoring of patients with tyrosinaemia
  type 1: Consensus group recommendations from the German-speaking countries'
date: '2024-12-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39676394/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241216171835&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Hepatorenal tyrosinaemia (HT1) is an autosomal recessive disorder of
  tyrosine degradation resulting in hepatic and renal dysfunction, neurological sequelae
  may occur in some patients. The use of nitisinone (NTBC) has revolutionised treatment
  and outcome of this disorder. NTBC has to be combined with a low protein diet. While
  NTBC modulates the disease course in HT1 patients, several issues are open. Optimal
  dosage, doses per day, therapeutic range of NTBC concentration, mode of ...
disable_comments: true
---
Hepatorenal tyrosinaemia (HT1) is an autosomal recessive disorder of tyrosine degradation resulting in hepatic and renal dysfunction, neurological sequelae may occur in some patients. The use of nitisinone (NTBC) has revolutionised treatment and outcome of this disorder. NTBC has to be combined with a low protein diet. While NTBC modulates the disease course in HT1 patients, several issues are open. Optimal dosage, doses per day, therapeutic range of NTBC concentration, mode of ...